Skip to content

Infants Fed Extensively Hydrolyzed Casein-Based Infant Formulas

Growth and Tolerance of Infants Fed Extensively Hydrolyzed Casein-Based Infant Formulas

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04006236
Enrollment
245
Registered
2019-07-05
Start date
2019-08-05
Completion date
2021-09-20
Last updated
2021-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant Development

Brief summary

This is a randomized, controlled, double-blind, multicenter parallel study to evaluate the growth, tolerance and compliance of healthy infants fed infant formulas with extensively hydrolyzed casein protein.

Interventions

Feed Ad Libitum

Feed Ad Libitum

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
0 Days to 14 Days
Healthy volunteers
Yes

Inclusion criteria

* Participant is judged to be in good health * Participant is a singleton from a full-term birth with a gestational age of 37-42 weeks * Participant's birth weight was \> 2490 g (\ 5 lbs. 8 oz.) * Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study * Parent(s) confirm their intention not to administer vitamins, minerals (with the exception of Vitamin D supplements), solid foods or juices to their infant from enrollment throughout the duration of the study * Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization

Exclusion criteria

* An adverse maternal, fetal or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development. * Participant is taking and plans to continue taking medications, home remedies, prebiotics, probiotics, herbal preparations or rehydration fluids that might affect gastrointestinal (GI) tolerance * Participant participates in another study that has not been approved as a concomitant study by AN. * Participant has an allergy or intolerance to any ingredient in the study product * Participant has been treated with antibiotics within 1 week prior to enrollment

Design outcomes

Primary

MeasureTime frameDescription
WeightDay of Age (DOA) 14 to 119Interval weight gain per day

Secondary

MeasureTime frameDescription
Head CircumferenceStudy Day (SD) 1 to DOA 119Interval HC gain per day
LengthStudy Day (SD) 1 to DOA 119Interval length gain per day
Stool CharacteristicsStudy Day (SD) 1 to DOA 119Parent Completed Diary
Formula IntakeStudy Day (SD) 1 to DOA 119Parent Completed Diary

Other

MeasureTime frameDescription
Formula Satisfaction QuestionnaireExit or DOA 119Parent completed questionnaire; 13 questions of up to 5 categories scaled in the negative direction
Infant Behavior QuestionnaireExit or DOA 119Parent completed questionnaire; 22 questions with 5 categories scaled in the negative direction
Infant Feeding and Stool Patterns QuestionnaireExit or DOA 119Parent completed questionnaire; 16 questions with 5 categories scaled in the negative direction

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026